BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Exein and Deutsche Telekom IoT Partner to Secure the Next Generation of Connected Devices7.10.2026 08:00:00 CEST | Press release
The companies will combine device-level security with global IoT connectivity to strengthen security for connected devices The partnership follows Exein's $270 million funding round, which included T.Capital, Deutsche Telekom's strategic investment arm, among its backers Exein, a global leader in physical AI and runtime security, today announced a strategic partnership with Deutsche Telekom IoT to bring integrated security to connected devices across Deutsche Telekom IoT’s ecosystem. With its own transatlantic network and around 600 roaming and satellite partners, Deutsche Telekom IoT provides worldwide connectivity for customers across industries and markets. The partnership pairs Exein's device-level security with Deutsche Telekom IoT’s global connectivity capabilities, addressing a gap that is becoming more urgent as intelligent, business-critical applications move directly onto devices operating in the field — robots, drones and industrial machines acting autonomously and making de
Stop Hoping for Secure AI and Start Building It: RSA Agent ID Closes the Agentic Identity Gap for Highly Regulated Industries7.10.2026 06:00:00 CEST | Press release
As AI, sovereignty, and board-level accountability converge on identity, RSA Agent ID enables finance, government, and regulated industries to find and register agents, prove the authority behind every consequential action, and run it where they choose At World Summit AI in the Netherlands, RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced RSA Agent ID, the agentic identity security platform for highly-regulated industries. RSA Agent ID discovers, secures, and governs AI agents across their lifecycle, letting regulated organizations find and register agents, prove the authority behind every consequential action, and run it where they choose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006426797/en/ Three forces are reshaping how organizations operate, and they are arriving at once. AI is transforming work and pushing agents into production faster than securit
The Empire State Building Observation Deck Hosts Annual Run-Up, Presented by NYU Langone Health and Powered by Merrell7.10.2026 04:25:00 CEST | Press release
The Empire State Building (ESB) hosted the 48th Annual Empire State Building Observation Deck Run-Up, presented by NYU Langone Health and powered by Merrell. In several designated heats, more than 200 runners from across the world raced up the building’s 1,576 stairs to reach the finish line on the iconic 86th Floor Observation Deck. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006766024/en/ The Empire State Building Observation Deck Hosts Annual Run-Up, Presented by NYU Langone Health and Powered by Merrell “Athletes gather from around the globe to participate in the Empire State Building Observation Deck Run-Up, the world’s preeminent tower race,” said Tony Malkin, chairman and CEO of Empire State Realty Trust. “We congratulate all who participated in this ultimate feat of endurance at Tripadvisor’s number one top attraction in the U.S.” Ryoji Watanabe of Japan took first place in the Men’s Elite heat with a time of 1
Phenom Adds Major Headline Speakers as IAMPHENOM Europe Approaches Sold-Out Status6.10.2026 15:30:00 CEST | Press release
Second wave of esteemed speakers to bring real-world guidance on applying AI, agents and automation to improve hiring, development and retention Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, today announced the newest wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006714151/en/ Phenom announced the newest wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. The two-day conference gives attendees what other HR events can’t: an inside look at AI agents already in production, automated workflows tailored to specific business contexts and the dramatic results they are already delivering. Across keynotes, customer
European Firms Struggle to Keep Pace with Growing DSAR Demands, New Reveal Study Finds6.10.2026 15:00:00 CEST | Press release
With 86% of organisations still lacking dedicated DSAR technology, fewer than half of requests are completed within the one-month window GDPR requires, even as spending climbs New research published today byReveal, the provider of integrated AI-native platforms spanning the dispute resolution lifecycle, found that large European organisations complete fewer than half of data subject access requests (DSARs) within the one-month deadline required under the General Data Protection Regulation (GDPR), a shortfall the study ties directly to a near-universal absence of purpose-built technology. Nearly nine in 10 organisations still run DSARs on manual or general-purpose workflows, with no dedicated tooling in place. The report, based on a survey of 213 legal and privacy professionals at large European enterprises, is the first of its kind to benchmark how organisations across the region are managing DSAR compliance at scale. The findings expose structural inconsistencies between how organisat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom